comparemela.com

Latest Breaking News On - Nemolizumab - Page 1 : comparemela.com

Jonathan Silverberg, MD, PhD: New Phase 3 Findings on Nemolizumab for Atopic Dermatitis

This interview at AAD featured a discussion with Silverberg on nemolizumab’s efficacy and safety at Week 48 among patients with moderate-to-severe atopic dermatitis.

United statesSan diegoJonathan silverbergGeorge washington university school of medicineEuropean academy of dermatologyAmerican academy of dermatologyHealth sciencesAnnual meetingGeorge washington university schoolEuropean academyInvestigator global assessmentAtopic dermatitisPhase 3

Biologics License Application for Nemolizumab Accepted by FDA for Prurigo Nodularis, Atopic Dermatitis

In addition to the newly-accepted BLA in the US, the European Medicines Agency also accepted the drug’s Marketing Authorization Application for both conditions.

Baldo scassellati sforzoliniDrug administrationEuropean medicines agencyBiologics license applicationsMarketing authorization applicationsPriority reviewBreakthrough therapyScassellati sforzoliniBiologics license applicationAtopic dermatitis

Shawn Kwatra, MD: Implications of New Data on Nemolizumab, Prurigo Nodularis

This segment of Dr. Kwatra’s latest interview featured a discussion on the future of prurigo nodularis treatment and the implications of his team’s research.

Shawn kwatraJohns hopkins university school of medicineJohns hopkins university schoolPrurigo nodularis

#VisualAbstract: Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Click to read this study in NEJM. VA design by Bryan Sun. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine,

Bryan sunMinute medicine incIl 13a antagonistPrurigo nodularisPrurigo nodularis treatment

Shawn Kwatra, MD: Discussing New Phase 3 Data on Nemolizumab for Prurigo Nodularis

In this interview, Dr. Kwatra explored the recent phase 3 data from the Olympia 2 study on nemolizumab treatment for patients with prurigo nodularis.

Shawn kwatraJohns hopkins university school of medicineJohns hopkins university schoolPrurigo nodularis

vimarsana © 2020. All Rights Reserved.